Titlebook: Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment; Roberto L. Ceriani Book 1994 The Editor(s) (if applic

倔強一點

神經(jīng)

,Vaccination Against Breast Cancer — Studies in an Animal Model,cols the death rate is still high due to failure of the response to treatment in metastatic cases.. Numerous factors set one tumor apart from another. Tumor specific markers are invaluable for diagnostic, prognostic and therapeutic purposes and enable the clinician to decide on treatment regimes.

桶去微染

arabesque

employor

Multivariate Prognostic Model for Infiltrating Ductal Carcinoma of the Breast in the Axillary Node-ycoproteins., some of them later detected in the sera of breast cancer patients.. Later, monoclonal antibodies (MoAbs) we created against HMFG first identified a heavy molecular weight glycoprotein., later called the breast epithelial mucin. This molecule, recently sequenced. possesses heterogeneous

Recessive

Genetics

會議

Suppression of Human Anti-Mouse Antibody Response to Murine Monoclonal Antibody L6 by Deoxyspergual have been used to modulate the host immune system to activate tumoricidal effector mechanisms and are being used as targeting vehicles for delivery of exogenous cytotoxic molecules such as radioisotopes, chemicals and biologicals. Their ability to selectively target tumor cells also makes them attr

gratify

Overview of Radioimmunotherapy in Advanced Breast Cancer Using I-131 Chimeric L6,esigned to determine the maximum tolerated dose (MTD) of radioimmunotherapy that could be administered at 4 intervals. Ten patients received 20 - 70 mCi/m. of .I ChL6. Two of the patients received granulocyte colony stimulating factor (GCSF) on days 10-20 post therapy. The MTD for two doses was 60 m

SOB